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The human papillomavirus type 18 (HPV-18) upstream regulatory region (URR) controls cell type-specific expression of the
viral oncoproteins E6 and E7. The HPV-18 URR is active in the cervical carcinoma cell line HeLa but inactive in the hepatoma
cell line HepG2. C/EBPß (NF-IL-6) was shown to participate as an important regulator in HPV transcription dependent on the
cell type. The finding that C/EPBß is critical for HPV-18 URR activity and that C/EPBß is induced by IL-6 offers the opportunity
of manipulating HPV activity by specific cytokine treatment. In this report, we show that treatment with IL-6 results in
activation of HPV-18 URR activity in HepG2 cells. In contrast, the HPV-18 URR is not inducible by IL-6 in three cervical
carcinoma cell lines. In all three cell lines we found decreased expression of the IL-6 receptor compared to the IL-6-
responsive HepG2 cells, whereas the level of expression of the signal transduction component gp130 is present in all cells.
These results suggest that cervical carcinoma cells may circumvent the IL-6-induced cellular defense mechanism through
downregulation of the IL-6-receptor. © 1999 Academic Press
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aINTRODUCTION
Interleukin-6 (IL-6) is a pluripotent growth-regulatory
ytokine which exerts diverse biological effects depend-
ng on the target cell type (Akira et al., 1993; Kishimoto,
989; Seghal, 1990). The levels of IL-6 and its receptor
ithin a given microenvironment, as well as the physiol-
gy of the IL-6 pathway, are critical factors required for
oth responsiveness and regulating normal cell function
Rose-John and Heinrich, 1994).
The IL-6 signal cascade is initiated after interaction of
L-6 with a ligand binding extracellular receptor subunit,
L-6R. In addition, the IL-6 receptor subunit is able to
elease a soluble IL-6 receptor by proteolytic cleavage
Akira et al., 1993; Rose-John and Heinrich, 1994). The
orresponding transmembranic subunit, gp130, which
eems to be almost unique to various cell types, is
equired for signal transduction. Binding of IL-6 to IL-6R
nitiates dimerization of IL-6R and gp130, following signal
ransduction by tyrosin phophorylation of gp130 (Mack-
ewicz et al., 1993; Rose-John and Heinrich, 1994). A
oluble form of human IL-6 receptor has been shown to
ind to IL-6 in solution and to induce biological response
o IL-6R2/gp1301 cells that are normally unresponsive to
L-6 (Mackiewicz et al., 1993; Narazaki et al., 1993).
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344In malignant cells, IL-6 may act as a potent growth
ctivator, particularly for plasmocytomas and myelomas
Kawano et al., 1988; Klein et al., 1989) and other nonhe-
atopoetic tumors (Miki et al., 1989; Miles et al., 1990;
atson et al., 1993). In contrast, in other malignancies
uch as leukemia, melanoma, and breast and lung can-
er, it was shown that IL-6 exerts an inhibitory effect to in
itro and animal tumor systems (Chen et al., 1988; Lu et
l., 1992; Revel, 1992; Takizawa et al., 1993; Sun et al.,
995).
Some cervical carcinoma cell lines have shown to
ynthesize IL-6, and autocrine as well as paracrine
echanisms have been suggested to promote prolifera-
ion (Eustace et al., 1993; Tartour et al., 1994; Iglesias et
l., 1995; Castrilli et al., 1997). The high-risk papillomavi-
us types, especially human papillomavirus HPV-16 and
PV-18, are believed to be the causal agents of cervical
ancer (zur Hausen, 1989, 1991a,b, 1996; Schiffman et al.,
993). E6 and E7 oncogenes are known to be relevant for
rogression to malignant growth. Their loss of function
auses proliferation arrest and cell death (von Knebel-
oeberitz et al., 1988, 1992). A number of transcription
actors have been reported to be important in the regu-
ation of HPV transcription (Kyo et al., 1993; Hoppe-Seyler
nd Butz, 1994; McCaffery and Jackson, 1994; Bauknecht
t al., 1996; Wang et al., 1996). In recent studies it was
hown that HPV-11, -16, and -18 as well as bovine pap-
llomavirus type 4 are strongly repressed by C/EBPß (Kyo
t al., 1993; McCaffery and Jackson, 1994; Bauknecht et
l., 1996; Wang et al., 1996). C/EBPß (NF-IL-6) was first
haracterized as a protein whose mRNA synthesis is
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345IL-6 AND CERVICAL CARCINOMAegulated by IL-6 and other cytokines (Akira et al., 1990).
embers of the C/EBP family consist of highly related
soforms, which bind to CCAAT box of several promoters
nd to a distinct core homology of viral enhancers (Akira
t al., 1993; Wedel and Ziegler-Heitbrock, 1995). The
/EBP family of proteins have common basic region
eucine zipper (bZIP) domains. Through the leucine zip-
er region, C/EBP proteins form homo- and heterodimers
ith other family members, with leucine zipper proteins
utside the family as well as non-leucine-zipper-contain-
ng proteins (Landschulz et al., 1989; Wedel and Ziegler-
eitbrock, 1995). Members of the C/EBP family have a
ighly conserved tissue distribution (Birkenmeier et al.,
989; Akira et al., 1993; Wedel and Ziegler-Heitbrock,
995) and targets for C/EPB proteins are liver- and dif-
erentiation-specific genes, cytokines genes, and in ad-
ition enhancer regions of diverse viruses (Birkenmeier
t al., 1989; Maire et al., 1989; Majello et al., 1990; Akira
t al., 1993; Wedel and Ziegler-Heitbrock, 1995).
In the present study, we examined the possibility of
egulating HPV-18 activity in response to the cytokine
L-6 by comparing three established HPV-18-positive cer-
ical carcinoma cell lines and an established hepatoma
ell line, HepG2. Transfection studies of HPV-18 up-
tream regulatory region (URR) reporter gene constructs
evealed a strong induction of URR activity by IL-6 in
epG2 cells. This IL-6-induced activation was dose de-
endent. In contrast, HPV-18 URR activity was not in-
uced by IL-6 in the three HPV-18-positive cervical car-
inoma cell lines HeLa, C4-1, and SW756. To understand
he mechanisms by which IL-6 has no effect on the
PV-18 URR activity in these cervical carcinoma cells,
e showed by Northern blot and RT–PCR analysis that
xpression of IL-6 receptor is strongly reduced in the
ested cervical carcinoma cell lines but not in HepG2
ells. Interestingly, different passages of HPV-16-trans-
ormed human keratinocytes revealed a reduced IL-6
eceptor expression in Northern blot analysis, depending
n the increasing passage number. In addition, flow
ytometry studies demonstrate a reduced IL-6 receptor
xpression in the cervical carcinoma cell lines as well as
n the high-passage HPV-16-transformed keratinocyte
ell line HPK IAP359. However, we found that the signal
ransduction component gp130 is present in all cells.
In summary, by using the HPV-18 URR as a test system
e have provided evidence that IL-6 has no effect on
RR activity, probably through a low-level expression of
he IL-6 receptor in different cervical carcinoma cells
ompared to the IL-6-responsive cell line HepG2. The
act that C/EBPß is strongly induced by IL-6 and that
PV-18 and other HPV types can be repressed by over-
xpression of C/EBPß points to a possible mechanism
y which cervical carcinoma cells could avoid a cellular
efense mechanism against transcription of viral onco-
roteins E6/E7. aRESULTS
L-6 activates HPV-18 expression in HepG2 cells
Active expression of HPV-18 E6 and E7 oncoproteins
s regulated by the URR. In recent reports it was shown
hat the HPV-18 URR exhibits stringent cell type specific-
ty and functions only in certain human epithelial cells
Bauknecht et al., 1992; Thierry et al., 1987; Bernard et al.,
989; Mack and Laimins, 1991). Mutational analyses of
he HPV-18 URR have shown that a sequence termed the
witch region contributes in a cell type-specific manner
o the high-level activity of the HPV-18 URR in HeLa cells
Bauknecht et al., 1995). It was shown that in HeLa cells
/EBPß forms an activating complex with YY1 which
inds to the switch region OL22 (Bauknecht et al., 1996).
n contrast, the HPV-18 URR is virtually inactive in HepG2
ells and this is believed to be due to the lack of
/EBPß–YY1 interaction, which ensures that YY1 func-
ions as an activator of the HPV-18 URR, as is the case in
eLa cells. Overexpression of C/EBPß in HepG2 cells
estores the C/EBPß–YY1 switch region interaction and
herefore activates the HPV-18 URR (Bauknecht et al.,
996). The finding that C/EBPß is critical for HPV-18
ctivity and that C/EBPß is regulated by the cytokine IL-6
ffers the opportunity of manipulating HPV-18 promoter
ctivity by IL-6 treatment. Therefore, we were interested
n analyzing the effect of IL-6 treatment on URR activity in
ifferent cervical carcinoma cell lines.
To determine if URR activity can be influenced by IL-6
e first analyzed the HPV-18 URR in HepG2 cells (Fig. 1).
PV-18 URR CAT plasmid p18URR was transfected into
epG2 cells, and after transfection cells were main-
ained in medium treated with various concentrations of
uman recombinant IL-6. After a 24-h period of IL-6
reatment extracts of transfected cells were prepared
FIG. 1. Induction of HPV-18 URR in HepG2 cells by IL-6 treatment.
reatment by IL-6 after 6 h of transfection significantly induced HPV-18
RR-driven CAT expression. CAT assays were carried out with extracts
repared from HepG2 cells transfected with 18 mg p18URR together
ith 0.5 mg of RSV/L as an internal control. CAT activities were quan-
ified relative to the activity obtained with p18URR without IL-6 treat-
ent (lanes 1 and 7), which was set at 0.1. The results of a represen-
ative CAT assay are shown. Lanes 1 and 7, without IL-6 treatment;
anes 2–6, increasing amounts of IL-6 from 800 to 2000 u IL/6/ml as
hown. Relative CAT activities were as follows: p18URR without IL-6,
.1; with 800 u IL-6/ml, 0.6; with 1000 u IL6/ml, 0.7; with 1200 u IL6/ml,
.2; with 1600 u IL6/ml, 1.0; with 2000 u IL6/ml, 0.95.nd assayed for CAT activity. As shown in Fig. 1, HPV-18
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346 BAUKNECHT ET AL.RR (p18URR) has a very low-level activity in HepG2
ells. Addition of IL-6 to the medium activated p18URR in
epG2 cells and URR activity reached a maximum level
ith about 1200 units IL-6/ml medium (Fig. 1). Activation
f the HPV-18 URR in HepG2 cells through overexpres-
ion of C/EBPß is accompanied by formation of the
/EBPß–YY1 switch region complex (Bauknecht et al.,
996). Mutations in the switch region that abolished the
omplex formation also abrogated C/EBPß-induced tran-
criptional activation in HepG2 cells (Bauknecht et al.,
996). To determine if IL-6-induced activation of the
PV-18 URR is dependent on a functional switch region,
FIG. 2. In contrast to wild-type HPV-18 URR, mutation of the C/EBPb–
ells. (A) HepG2 cells were transfected with 18 mg of the wild-type co
ontrol without IL-6 treatment; columns 2–5, increasing amounts of IL-6
he HPV-18 URR CAT plasmid containing the mutated C/EBPb/YY1 site
ctivities were quantified relative to the activity of the control transfecti
ith 400 u IL-6/ml, 0.58; with 800 u IL-6/ml, 0.66; with 1000 u IL-6/ml, 0.6
L-6, 0.1; with 400 u IL-6/ml, 0.2; with 800 u IL-6/ml, 0.15; with 1000 u ILPV-18 CAT plasmids containing mutations in the switch Iegion (p18URR-22M1) were transfected into HepG2
ells and treated with the same amount of IL-6 as in Fig.
and extracts of transfected cells were analyzed for CAT
ctivity (Fig. 2). In parallel, HepG2 cells were transfected
ith wild-type p18URR to control for the quality of the
pplied IL-6. In contrast to IL-6-induced activation of
ild-type HPV-18 URR (p18URR) (Fig. 2A) mutations of the
/EBPß–YY1 binding site in the context of the HPV-18
RR (plasmid p18URR-22M1, containing OL22M1, the
utated switch region) prevented activation of the
PV-18 URR by IL-6 in HepG2 cells (Fig. 2B). These
esults demonstrate that activation of the HPV-18 URR by
itch region OL22 prevents induction of HPV-18 URR by IL-6 in HepG2
p18URR together with 0.5 mg RSV/L as an internal control. Column 1,
00 u/ml. (B) HepG2 cells were transfected with 18 mg of p18URR-22M1,
1, together with 0.5 mg RSV/L as an internal control. In A and B, CAT
out IL-6 treatment), which was set at 0.1. (A) p18URR without IL-6, 0.1;
1200 u IL-6/ml, 1.18; with 1600 u IL-6/ml, 0.98. (B) p18URR-22M1 without
0.13; with 1200 u IL-6/ml, 0.1; with 1600 u IL-6/ml, 0.13.YY1 sw
nstruct
up to 16
OL22M
on (with
8; with
-6/ml,L-6 in HepG2 cells is restricted to a functional switch
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347IL-6 AND CERVICAL CARCINOMAegion, which is in accordance with what was shown for
/EBPß-induced activation of the HPV-18 URR in HepG2
ells (Bauknecht et al., 1996).
In contrast to HepG2 cells where overexpression of
/EBPß was shown to activate the HPV-18 URR, HPV-18
RR activity is repressed by C/EBPß in HeLa cells
Bauknecht and Shi, 1998). To determine the effect of
/EBPß in other cervical carcinoma cells, we performed
FIG. 3. (A and B) Overexpression of C/EBPb in the cervical carcinoma
ell line was transfected with 18 mg of p18URR together with increasing
ell lines: (A) C4-1 and (B) SW 756. Column 1, control; columns 2–5, inc
uantified relative to the activity of the control transfection, with only 18
ere as follows: control, 1.0; 3 mg pcDNAI, 0.95; 5 mg pcDNAI, 0.92; 3
cDNAI, 0.93; 3 mg C/EBPb, 0.25; 5 mg C/EBPb, 012.otransfection studies of the HPV-18 URR CAT construct hnd the C/EBPß expression plasmid in C4-1 and SW756
ells (Fig. 3). Overexpression of C/EBPß resulted in a
ownregulation of the HPV-18 URR in both cell lines,
imilar to that shown in HeLa cells.
Next we analyzed the effect of IL-6 on HPV-18 URR
ctivity in HeLa cells in which the URR activity is strongly
uppressed by overexpression of C/EBPß. As shown in
ig. 4, addition of IL-6 (up to 2000 units IL-6/ml medium)
4-1 and SW756 results in downregulation of HPV-18 URR activity. Each
ts of CMV-C/EBPb (lanes 2–5) and 1.0 mg RSV/L as an internal control.
amounts of cotransfected CMV-C/EBPb plasmid. CAT activities were
URR and 1.0 mg RSV/L, which was set at 1.0. (A) Relative CAT activities
BPb, 0.3; 5 mg C/EBPb, 0.16. (B) Control, 1.0; 3 mg pcDNAI, 0.95; 5 mgcells C
amoun
reasing
mg p18
mg C/Ead no effect on HPV-18 promoter activity. Similar results
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348 BAUKNECHT ET AL.ere observed with the HPV-18-positive cervical carci-
oma cell lines SW756 and C4-1, as the transfected
PV-18 URR CAT construct p18URR was not affected in
ither cell line by IL-6 treatment (data not shown). These
esults suggest that in HeLa, SW756, and C4-1 cells one
r several components of the IL-6/IL-6 receptor complex
r a mechanism in signal transduction might be affected
nd prevent induction of C/EBPß in these cells.
L-6 receptor complex: Expression of the 80-kDa IL-6
inding receptor protein (IL-6R)
As described above, reduced expression of one of the
L-6 receptor complex components could be responsible
or the nonresponsiveness of the HPV-18 URR to IL-6
reatment in the cervical carcinoma cell lines HeLa,
W756, and C4-1. To define this component, we first
nalyzed the expression of the 80-kDa IL-6R component
n each cervical carcinoma cell line and in HepG2 cells
y RT–PCR and Northern blot. When we analyzed the
ells by RT–PCR for expression of IL-6R (Fig. 5A) we
bserved a strong signal in HepG2 cells (lane 9) com-
ared to slight signals in HeLa (lane 8), C4-1 (lane 7), and
W756 cells (lane 6). Lanes 1 to 4 demonstrate the
-actin control with each sample of the different cell
ines. Lanes 5 and 10 demonstrate the controls with
ater. The same difference was observed when we
FIG. 4. In HeLa cells, HPV-18 URR activity is not affected by the C/EB
lanes 7 to 12) of p18URR together with 0.5 mg RSV/L as an internal co
8 h. CAT activities were quantified relative to the activity obtained with
et at 1.0 [for 1 mg of transfected DNAs (lanes 7 to 12), the activities are
(1 mg of p18URR), without IL-6 treatment; lanes 2 to 6 (2 mg of p18UR
o 2000 u IL-6/ml. Relative CAT activities were as follows: lane 1 (cont
IL6/ml), 1.0; lane 5 (1600 u IL6/ml), 1.04; lane 6 (2000 u IL6/ml), 1.0; lan
0 (1200 u IL6/ml), 0.52; lane 11 (1600 u IL6/ml), 0.5; lane 12 (2000 u ILnalyzed IL-6 receptor mRNA expression by Northern ilot (Fig. 5B). As shown in Fig. 5A, in contrast to HepG2
ells, in each of the three cervical carcinoma cell lines
e detected only a very weak expression of endogenous
L-6 receptor mRNA by Northern blot analyses (Fig. 5B).
Flow cytometry analyses for quantification of the IL-
R-positive cells were performed. In addition to several
ervical carcinoma cell lines we add to our analyses of
he IL-6R expression two different passages of HPV-16-
ransformed human keratinocytes, low-passage-number
PK IAP49 cells, and high-passage HPK IAP359 cells.
ecently, high-passage-number HPK cells were shown
o be tumorigenic (Du¨rst et al., 1995). Cell surface ex-
ression of IL-6 receptor was examined in comparison of
he binding reactivities of a specific anti-IL-6 receptor
Ab with that of an isotype-matched control MAb. Their
luorescence profiles are shown in Fig. 6. Significant
taining was observed in HepG2, with a positivity of over
6% for IL-6R. When we analyzed the cervical carcinoma
ell lines HeLa, C4-1, and SW756 we observed with HeLa
ells an over 50% reduced expression of IL-6R compared
o HepG2 cells (Fig. 6). Moreover, our analysis of C4-1 as
ell as SW756 cells revealed a complete downregulation
f the IL-6 receptor in these cells. Interestingly, when we
nalyzed HPK IAP49 and HPK IAP359 cells, we observed
hat the low-passage-number HPK IAP49 cells of HPV-
6-transformed human keratinocytes give rise to a more
ucer IL-6. HeLa cells were transfected with 2 mg (lanes 1 to 6) or 1 mg
reatment with IL-6 was carried out 6–24 h after transfection for up to
R without IL-6 treatment (2 mg of transfected DNA) (lane 1), which was
ified relative to p18URR set at 1, lane 1]. Lanes 1 (2 mg of p18URR) and
lanes 7 to 12 (1 mg of p18URR), increasing amounts of IL-6 from 800
; lane 2 (800 u IL6/ml), 1.04; lane 3 (1000 u IL6/ml), 0.98; lane 4 (1200
ntrol), 0.5; lane 8 (800 u IL6/ml), 0.48; lane 9 (1000 u IL6/ml), 0.51; lane
0.49.Pb ind
ntrol. T
p18UR
quant
R) and
rol), 1.0
e 7 (contensive IL-6R expression signal than the high-passage-
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349IL-6 AND CERVICAL CARCINOMAumber HPK IAP359 cells and the cervical carcinoma
ell line HeLa (Fig. 6).
L-6 receptor complex: Expression of the 130-kDa
ignal transducing protein (gp130)
After binding of IL-6 to its receptor, the ligand–receptor
omplex is associated with gp130, the signal-transduc-
ng component of the IL-6 receptor (Rose-John and Hein-
ich, 1994). The exact mechanism of signal transduction
y the IL-6 receptor complex is still not known, although
t has been reported that dimerization of gp130 initiates
ignal transduction via the JAK/STAT pathway (Akira et
l., 1994; Lutticken et al., 1994; Stahl et al., 1994; We-
enka et al., 1994; Zhong et al., 1994). IL-6 stimulation
as also been shown to activate RAS and mitogen-
ctivated protein kinases (MAPK) that are essential for
/EBPß (NF-IL-6) activation (Nakajima et al., 1993).
Determination of expression of gp130 at the mRNA
evel by RT–PCR indicates that gp130 is expressed in all
ell lines (Fig. 7). The expression of gp130 mRNA in the
L-6-responsive cell line HepG2 was used as a control.
hese results are consistent with previous reports show-
ng that gp130 is expressed in nearly all examined hu-
an and mouse cell lines (Taga and Kishimoto, 1992;
anapathi et al., 1996). This is not surprising since gp130
as been shown to be signal transducer for several other
ytokines with overlapping biological functions, includ-
ng IL-11, leukemia inhibiting factor (LIF), oncostatin M
OSM), ciliary neurotrophic factor (CNTF), and cardiotro-
hin-1 (CT-1) (Gearing et al., 1992; Ip et al., 1992; Liu et
l., 1992; Yin et al., 1993; Pennica et al., 1995).
DISCUSSION
The HPV URR controls transcription of the E6 and E7
FIG. 5. RT–PCR and Northern blot analysis of IL-6 receptor (IL-6R
xpression by RT–PCR. Only weak signal intensities were observed in
n lanes 1–4, b-actin was amplified to normalize PCR products obtaine
nd 10. Lane 1, SW756; lane 2, C4-1; lane 3, HeLa; lane 4, HepG2; lane
B) Analysis of IL-6R expression by Northern blot. On the bottom, RNA lo
or IL-6 receptor expression. Lanes 2–4 show weak expression of IL-6ncogenes which are involved in the carcinogenesis of CPV-induced cervical cancer. The transcription factor
/EBPß plays an important role in the transcriptional
egulation of HPV-18. In HeLa cells, C/EBPß forms a
omplex with YY1 and contributes to about 50% of the
RR activity. In several reports it was shown that the
PV-18 URR has a very high activity in HeLa cells but is
nactive in HepG2 cells (Bauknecht et al., 1995, 1996).
verexpression of C/EBPß in HepG2 cells was shown to
ctivate the HPV-18 URR by forming a C/EBPß–YY1 com-
lex which binds to the switch region OL22 in the HPV-18
RR (Bauknecht et al., 1996). In contrast, a further in-
rease of C/EBPß in HeLa cells by its overexpression
esults in strong repression of HPV-18 URR activity
Bauknecht and Shi, 1998). It was shown that overexpres-
ion of C/EBPß in HeLa cells specifically interferes with
BP binding to the TATA box of the HPV-18 URR, but not
n HepG2 cells, where it activates the URR (Bauknecht
nd Shi, 1998).
C/EBPß (NF-IL-6) is regulated by IL-6 at the level of
oth transcription and posttranslational modifications
Akira et al., 1990; Wedel and Ziegler-Heitbrock, 1995).
he strong repression effect of C/EBPß on HPV-18 URR
ctivity by its overexpression in HeLa cells lets us sug-
est that IL-6 treatment should result in similar repres-
ion of HPV-18 URR activity.
In this report we have shown that HPV-18 URR is
ctivated in HepG2 cells by IL-6 treatment (Fig. 1). This
ctivation is similar to that seen when C/EBPß is over-
xpressed in HepG2 cells (Bauknecht et al., 1996) and
emonstrates an intact C/EBPß induction pathway. Re-
ently, the OL22M1 mutation of the switch region se-
uence was shown to be defective in competition for the
ormation of the C/EBPß–YY1 complex in gel retardation
ssays. This provided a correlation between binding of
ssion in cervical carcinoma and HepG2 cells. (A) Analysis of IL6-R
and C4I cells. The marker X174 was digested with HaeIII. As controls
different cell lines. Additional controls with H2O are shown in lanes 5
lane 6: SW756; lane 7, C4-I; lane 8, HeLa; lane 9, HepG2; lane 10, H2O.
f the gel is shown. HepG2 cells (lane 1) were used as a positive control
or in different cervical carcinoma cell lines.) expre
SW756
d from
5, H2O;
ading o/EBPß to the switch region and the ability of C/EBPß to
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350 BAUKNECHT ET AL.ctivate the HPV-18 URR in HepG2 cells (Bauknecht et
l., 1996). As we could demonstrate that p18URR-22M1 is
ot activated by IL-6 in contrast to wild-type HPV-18 URR
p18URR) (Fig. 2), we conclude that activation of URR by
L-6 is restricted to the switch region of the HPV-18 URR.
owever, it was not possible to induce any IL-6 response
n the HPV-18-positive cervical carcinoma cell lines HeLa
Fig. 4). No effect on URR activity was observed when
4-1 and SW756 cells were treated with IL-6 (data not
hown). In this regard it will also be interesting to ana-
yze the effect of IL-6 on the HPV-18 URR after introduc-
ion into primary keratinocytes.
It can be postulated that induction of C/EBPß would
ave a strong repression effect on HPV-18 URR activity,
imilar to that seen when C/EBPß is overexpressed in
eLa cells. In addition it was shown that overexpression
FIG. 6. Flow cytometric analysis of the cell surface expression of
L-6R by various tumor cell lines stained with an anti-IL-6R MAb (heavy
ine) and an isotype-matched control MAb (thin line). Bound antibodies
ere detected with biotinylated goat F/ab2, anti-mouse IgG1, and R-
tPE-SA. X-axis, log10 of FL-2 intensity; Y-axis, relative cell number. (%)
ercentage of cells being positive for IL-6R expression. Details are
escribed under Materials and Methods.f C/EBPß also causes significant downregulation of the SPV-18 E6/E7 mRNA level in HeLa cells (Bauknecht and
hi, 1998). It was reported that reduced E6/E7 expres-
ion negatively affects the growth rate of cervical carci-
oma cells (von Knebel-Doeberitz et al., 1988; Kyo et al.,
993). Therefore, it is not unexpected that cervical carci-
oma cells seem to lack an intact IL-6/C/EPBß pathway.
his is in accordance with our analysis of two other
ervical carcinoma cells demonstrating that overexpres-
ion of C/EBPß strongly represses HPV-18 URR activity
Figs. 3A and 3B), as in the case in HeLa cells. In this
ontext it seems interesting to analyze if introduction of
n E6/E7 heterologous expression system results in
ownregulation of HPV-18 URR responsiveness to IL-6 in
epG2 cells.
Iglesias et al. (1995) reported that in normal cervical
pithelium, the presence of HPV-16 or -18 DNA signifi-
antly decreased the expression of cytokines, including
L-1ß, IL-8, and IL-6, compared to normal epithelium.
oth IL-6 receptor and its signal transducer gp130 could
e detected in all cell lines by RT–PCR (Figs. 5 and 7).
owever, Northern blot analyses revealed in all cervical
arcinoma cells lines strongly reduced expression levels
f IL-6 receptor compared to the IL-6-responsive HepG2
ells (Fig. 5B). The percent quantification of flow cytom-
try data with the different cell lines supports this obser-
ation (Fig. 5A). As shown in Fig. 6, flow cytometry anal-
sis detected a significantly higher amount of IL-6 recep-
or in the HepG2 and HPK IAP49 cell lines than in the
hree cervical carcinoma cell lines HeLa, C4-1, and
W756 and the high-passage-number cell line HPK
AP359, which was shown to be tumorigenic (Du¨rst et al.,
995). The reported results point to an involvement of the
L-6 expression level in the process of HPV-induced
arcinogenesis. Our current analyses of cervical tumors
upport this suggestion (Bauknecht and Bauknecht, un-
ublished results). We are planning to analyze a larger
umber of tumors to clarify if reduced levels of IL-6R are
PV specific. In this context it will be interesting to
nalyze if there is a difference in IL-6 responsiveness of
FIG. 7. Expression of gp130 mRNA in different cell lines analyzed by
T–PCR. RT–PCR was performed with 25 cycles. Expected signals
ere detected with a 690-bp fragment (lanes 6–9). Lanes 1–4, b-actin
as amplified to normalize PCR products from different cell lines
660-bp fragment). Lanes 5 and 10 show controls with H2O. Lane 1,
W756; lane 2, C4-1; lane 3, HeLa; lane 4, HepG2; lane 5, H2O; lane 6,
W756; lane 7, C4-1; lane 8, HeLa; lane 9, HepG2; lane 10, H2O.
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351IL-6 AND CERVICAL CARCINOMAhe HPV-16 URR in early versus late passage HPV-16
mmortalized keratinocytes by analyzing endogenous
PV-16 mRNA expression in the two cell lines HPK IAP49
nd HPK IAP359.
Reduced expression of IL-6 receptor may not be the
ole cause of the nonresponsiveness of the cervical
arcinoma cell lines against IL-6 treatment. The mecha-
ism for IL-6 resistance in cervical carcinoma cells may
nvolve defects not only on the level of IL-6 receptor
xpression but also steps further downstream of the
ignal cascade. As shown in our flow cytometry studies,
eLa cells express significantly more IL-6 receptor mol-
cules than C4-1 or SW756 cells (Fig. 6). We are currently
nalyzing if other components of the signal transduction
ascade are affected in HeLa cells (Bauknecht and
auknecht, unpublished results).
Tumor development and progression are often accom-
anied by the alteration of response to cytokines and
rowth factors and the disruption of the balance between
egative and positive proliferation signals may provide
rowth advantages. IL-6 has been reported to act as a
rowth factor of normal squamous epithelial cells (Yo-
hizaki et al., 1990). In view of the lack of the IL-6
eceptor it seems to be controversial that IL-6 was
hown to act as a growth factor in cervical carcinoma
ells. Iglesias et al. (1995) demonstrated in HPV-16- and
PV-18-transformed cervical cell lines an EGF-receptor-
ependent pathway involving autocrine stimulation of
rowth factors by IL-6. In our study we could not detect
hanges in growth behavior after IL-6 treatment of HeLa,
4-1, SW756, HPK IA49, and HPK IA359; this was ana-
yzed by cell counting, BrdU proliferation assay, and cell
ycle analysis (data not shown). However, we have not
sed IL-6 antibodies. Their application to the medium of
ultured cervical carcinoma cell lines has been shown to
nduce growth repression (Eustace et al., 1993; Tartour et
l., 1994). Takano et al. (1996) reported a high diversity of
L-6 production and its receptor expression in several
ervical dysplasia and carcinoma cell lines. Due to this
bservation he concluded that there was a loss of IL-6
ignal transduction capability in the course of progres-
ion of dysplasia to cervical carcinoma (Takano et al.,
996). In conclusion, this study supports the theory that
here is a heterogenic mechanism by which tumor cells
cquire changes and resistance to specific signal trans-
uction pathways, achieving more growth advantage.
urther investigations have to focus on expression pat-
erns of IL-6 receptor in the course of different steps of
ysplasias to carcinoma tissues.
MATERIALS AND METHODS
ell culture and reagents
HepG2 (human hepatocellular carcinoma) as well as
he HPV-18-positive cell lines C4-1, HeLa, and SW756
cervix carcinoma) were obtained from ATCC (Rockville, iD). HPK IAP49 and HPK IAP359, representing increas-
ng passages of HPV-16-transformed human keratinocyte
ell lines, were kindly provided by Dr. M. Du¨rst (gyna¨-
ologische Molekularbiologie, Universita¨t Jena, Ger-
any). Tumor cells were maintained as monolayers in
ntibiotic-free D-MEM medium supplemented with N-
cetyl-L-alanyl-L-glutamine and 10% heat-inactivated FCS
PAA, Linz, Austria) in a humidified atmosphere of 5% CO2
t 37°C.
Human recombinant IL-6 was purchased from Boeh-
inger (Mannheim). Phycoerythrin-conjugated streptavi-
in (R-PE-SA) was purchased from Coulter-Immunotech
Hamburg, Germany). Anti-IL-6R MAb (B-N12, anti-gp80
gG1) was obtained from BioSource (Ratingen, Germany),
nd biotin-conjugated goat F(ab9)2 anti-mouse IgG1 from
oulter-Immunotech. Isotype-specific mouse IgG1 was
urchased from Southern Biotechnology Associates (Bir-
ingham, AL).
ransfection and CAT assay
HeLa, SW756, and C4-1 were transfected by the cal-
ium phosphate coprecipitation method (Chen and
kayama, 1987). Transfections were performed as de-
cribed (Chen and Okayama, 1987) and were done with
to 18 mg HPV-18 URR CAT containing reporter con-
tructs, 3 and 5 mg of the cytomegalie (CMV)-driven
/EBPb expression plasmid (CMV-C/EBPb), and 0.5 to 1
g RSV/L as an internal control (de Wet et al., 1987).
lasmid p18URR contains the complete HPV-18 URR
nucleotides 6930 to 103 of the HPV-18 genome) fused to
he CAT gene of pBLCAT3 as previously described
Bauknecht et al., 1992). p18URR-22M1 contains HPV-18
RR with a mutation in the switch region (Bauknecht et
l., 1996). Cytokines were applied after transfections.
AT assays were performed by using extracts with equal
uciferase counts. To circumvent a possible effect of the
ffector plasmid expressing C/EBPb on the cotrans-
ected RSV–luciferase construct RSV/L, CAT assays were
lso performed in parallel, using the same protein con-
entrations. To circumvent a possible IL-6 induction of
he cotransfected RSV–luciferase construct, transfected
ells were, after an overnight exposure to the precipi-
ates, split in a 1:2 ratio on tissue plates and medium was
dded to each transfection with and without IL-6. After
reatment, CAT assays were performed by using equal
mounts of luciferase counts of the nontreated cells with
he same protein amount of the appropriate IL-6-treated
ells. All transfections were repeated at least five times.
uantification of CAT assays was performed only when
he percentage of acetylated CAM was below 80%, for
he assay to be within the linear range. CAT activities
ere quantified by cutting spots from thin-layer chroma-
ography plates and determining the radioactivity by liq-
id scintillation. Results from individual transfection var-ed less than 20%.
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352 BAUKNECHT ET AL.NA extraction and RT–PCR
Total cellular RNA was prepared using the guanidium
hiocyanate method (Chomczynski and Sacchi, 1987).
everse transcription was performed on 1 mg of total
NA followed by PCR amplification. b-actin was ampli-
ied as an external control for equalizing the obtained
DNA from the different cell lines.
For interleukin-6 receptor (IL-6R) analysis, a primer
air corresponding to nucleotide positions 544 to 564
nd 763 to 784 of psBSF2R.236 was used (Yamasaki et
l., 1988). Amplification of gp130 was initiated by primers
orresponding to nucleotides 1767–1791 of the coding
trand, respectively, 2480 to 2456 to the noncoding
trand (Hibi et al., 1990). A single amplified product of the
redicted size was obtained for IL-6R (240 bp), gp130
690 bp), and b-actin (661 bp). Thirty cycles for IL-6R and
5 cycles for gp130 were performed and the PCR prod-
cts were electrophoresed on an 2% agarose gel.
orthern blot
Total cellular RNA (15 mg) was denatured and electro-
horesed in 1% agarose gels and transferred to nitrocel-
ulose filters (Hybond N,1 Amersham, Buckinghamshire,
K). Filters were prehybridized for 1–3 h at 42°C in 50%
eionized formamide, 53 SSPE, 53 Denhardt’s solution,
.5% sodium dodecyl sulfate (SDS), and 20 mg/ml dena-
ured salmon DNA. The 1.7-kb XhoI–XhoI fragment of the
uman IL-6 receptor cDNA (pBSF2R.236) was used as a
robe and labeled with 32P by the random oligonucleo-
ide method. Hybridization was carried out at 42°C in the
ame buffer, with the addition of 1 3 106 cpm/ml of the
abeled probe. After hybridization, the filters were
ashed three times in 23 SSC plus 0.1 sodium dodecyl
ulfate for 5 min at room temperature, followed by three
ashes in 0.13 SSC plus 0.1% sodium dodecyl sulfate for
5 min at 50°C. Filters were exposed to Kodak X-OMAT
ilm for 2–5 days. Filters were subsequently rehybridized
o a human b-actin probe to ascertain the differences in
NA loading among the different samples.
low cytometric analysis
Cell surface expression of IL-6R by tumor cells was
ssessed on a FACScan cytometer with laser excitation
t 488 nm (Becton–Dickinson, Mountain View, CA) using
tandard instrument parameters. Flow data was col-
ected on forward- and side-scattered gated populations.
en thousand events per sample were acquired as list
ode data and the files analyzed using Lysis II software.
ata were evaluated by determining the difference of the
ean channel fluorescence intensity (MFI) of cell popu-
ations stained with the specific and control MAbs. Cells
0.5 3 106/10 ml) were harvested with PBS without Ca21,
g21 containing trypsin/EDTA (0.05%/0.02%, w/v). In out-
ine, the method depends on a high-sensitivity three-ayer staining, all steps being performed at 4°C with
ce-cold labeling puffer (PBS without Ca21, Mg21 supple-
ented with 3% heat-inactivated FCS and 0.05% NaN3)
nd using the following incubation sequence: (1) uncon-
ugated anti-IL-6R MAb (25 ml, 12 mg/ml/106 cells), 120
in in the dark, (2) biotin-conjugated goat F(ab9)2 anti-
ouse IgG1 (5 ml, 5 mg/ml), 45 min in the dark, and (3)
-PE-SA (25 ml, 2.5 mg/ml), 45 min in the dark. After
entrifugation, cells were resuspended in 200 ml pro-
idium iodide (5 mg/ml labeling puffer) to stain and ex-
lude dead cells. Control stainings included an irrele-
ant, isotype-matched mouse IgG1 MAb.
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